合成利尿钠肽在心力衰竭治疗中的研究进展  

Designer Natriuretic Peptide in Treatment of Heart Failure

作　　者：冉倩 张翠[1] 杨波[1] RAN Qian;ZHANG Cui;YANG Bo(Department of Cardiology,Renmin Hospital of Wuhan University,Cardiovascular Research Institute,Wuhan University,Hubei Key Laboratory of Cardiology,Wuhan 430060,Hubei,China)

机构地区：[1]武汉大学人民医院心内科武汉大学心血管病研究所心血管病湖北省重点实验室,湖北武汉430060

出　　处：《心血管病学进展》2021年第9期788-791,共4页Advances in Cardiovascular Diseases

基　　金：国家自然科学基金(81500278)。

摘　　要：近年来在心力衰竭治疗方面取得了明显进展,但死亡率仍然很高。传统疗法通常不足以完全覆盖心力衰竭的心脏结构、功能、神经体液和肾脏机制之间的复杂相互作用。然而,利尿钠肽系统提供了一种独特的多效性策略,可满足心力衰竭治疗中的这一需求。外源性给予A型(卡必利肽)和B型(奈西利肽)利尿钠肽具有许多优点,但伴随着局限性。另外,通过合成修饰利尿钠肽产生的“合成利尿钠肽”有可能增加治疗效益。现介绍以利尿钠肽为基础的心力衰竭治疗方法的进展,包括新型嵌合型利尿钠肽CD-NP、CRRL269和利尿钠肽突变体mANP的设计、原理和初步研究。Recently,although great developments have been achieved in the treatment of heart failure,the mortality remains high.The networks of heart structure,function,neurohumoral and renal mechanisms are complicated that traditional therapeutic strategies are not able to completely cover.However,the natriuretic peptide system provides a unique pleiotropic strategy which are likely to meet this need in heart failure therapy.Exogenous administration of A-type(carperitide)and B-type(nesiritide)natriuretic peptides have many advantages,however,accompanied by limitations.In addition,designer natriuretic peptide,which is created by synthetic modification of natriuretic peptide,may increase the therapeutic efficacy.This review illustrates the progress of natriuretic peptide-based therapy for heart failure,including the design,rationale and preliminary research of novel chimeric natriuretic peptide CD-NP,CRRL269 and mutant natriuretic peptide mANP.

关 键 词：心力衰竭 利尿钠肽 CD-NP CRRL269 mANP 

分 类 号：R54[医药卫生—心血管疾病]